Third Arc Bio vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecific T cell engager, CLDN6+) in Phase 1 solid tumors. Platform spans oncology and autoimmune.
About
Third Arc Bio raised a $52 million Series A extension in February 2026 with Andreessen Horowitz as a new investor, building on its prior $165 million Series A to reach $217 million in total financing. The company develops multifunctional antibodies — protein therapeutics that combine multiple mechanisms of action in a single molecule — with its lead program ARC101 being a bispecific T cell engager targeting CLDN6 in solid tumors, currently in Phase 1 clinical trials.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.